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Abstract
Background: The use of mesenchymal stem cells (MSCs) to treat inflammatory bowel disease (IBD) is of great
interest because of their immunomodulatory properties. Damage to the enteric nervous system (ENS) is implicated
in IBD pathophysiology and disease progression. The most commonly used model to study inflammation-induced
changes to the ENS is 2,4,6-trinitrobenzene-sulfonate acid (TNBS)-induced colitis in guinea pigs; however, no studies
using guinea pig MSCs in colitis have been performed. This study aims to isolate and characterise guinea pig MSCs
and then test their therapeutic potential for the treatment of enteric neuropathy associated with intestinal
inflammation.
Methods: MSCs from guinea pig bone marrow and adipose tissue were isolated and characterised in vitro. In in
vivo experiments, guinea pigs received either TNBS for the induction of colitis or sham treatment by enema. MSCs
were administered at a dose of 1 × 106 cells via enema 3 h after the induction of colitis. Colon tissues were
collected 24 and 72 h after TNBS administration to assess the level of inflammation and damage to the ENS. The
secretion of transforming growth factor-β1 (TGF-β1) was analysed in MSC conditioned medium by flow cytometry.
Results: Cells isolated from both sources were adherent to plastic, multipotent and expressed some human MSC
surface markers. In vitro characterisation revealed distinct differences in growth kinetics, clonogenicity and cell
morphology between MSC types. In an in vivo model of TNBS-induced colitis, guinea pig bone marrow MSCs were
comparatively more efficacious than adipose tissue MSCs in attenuating weight loss, colonic tissue damage and
leukocyte infiltration into the mucosa and myenteric plexus. MSCs from both sources were equally neuroprotective
in the amelioration of enteric neuronal loss and changes to the neurochemical coding of neuronal subpopulations.
MSCs from both sources secreted TGF-β1 which exerted neuroprotective effects in vitro.
Conclusions: This study is the first evaluating the functional capacity of guinea pig bone marrow and adipose
tissue-derived MSCs and providing evidence of their neuroprotective value in an animal model of colitis. In vitro
characteristics of MSCs cannot be extrapolated to their therapeutic efficacy. TGF-β1 released by both types of MSCs
might have contributed to the attenuation of enteric neuropathy associated with colitis.
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Background
Inflammatory bowel disease (IBD), comprising ulcera-
tive colitis and Crohn’s disease, is a chronic debilitating
disorder currently increasing in incidence and preva-
lence [1]. Patients experience severe manifestations, in-
cluding bloody stool, persistent diarrhoea or constipation
(or both), abdominal pain, ulcerations, fistulae, structuring
and perianal fissures [2]. Current treatment options in-
clude anti-inflammatory drugs (aminosalicylates), cortico-
steroids, immunomodulators (thiopurines, methotrexate
and cyclosporine) and biological agents (anti-tumour ne-
crosis factor-alpha); these treatments either are toxic in
the long term or frequently fail to induce and maintain re-
mission [3]. Patients unresponsive to therapy require re-
moval of inflamed bowel segments; incidentally, almost
30 % of patients with Crohn’s disease will undergo their
first bowel resection surgery within 7 years of diagnosis
and subsequently require repeated surgeries [4]. There-
fore, investigations into alternative therapies for IBD are
essential. Recently, there has been interest in the use of
probiotics to treat IBD (e.g., Mutaflor) with positive results
achieved in some clinical trials [5]. Using live cells to mod-
ify the inflammatory response, as opposed to conventional
drugs, remains an intriguing prospect.
In the past decade, mesenchymal stem cells (MSCs),
also known as multipotent stromal cells, have emerged
as a clinically viable therapy for many diseases, includ-
ing IBD [6–8]. MSCs are defined by their differentiation
capacity, adherence to plastic in standard culture and
expression of specific surface markers [9]. MSCs are
easily isolated from adult tissue sources, including adi-
pose tissue and bone marrow; they are highly proliferative
and fibroblast-like in appearance and form monolayer col-
onies in culture [10–13]. Furthermore, MSCs can be suc-
cessfully transplanted between individuals and across
species as they have been shown to be immune-evasive
[14, 15]. The presence of chemokine receptors on MSCs
facilitates their migration toward inflammatory sites [16].
Once engrafted, MSCs suppress inflammation by immu-
nomodulation via secretion of anti-inflammatory media-
tors [17]. MSCs can also exert regenerative effects
through the secretion of pro-angiogenic and trophic
factors which promote endogenous mechanisms of re-
pair [18–20]. These properties make MSCs an attractive
therapeutic option for IBD and have been widely stud-
ied in experimental colitis models and more recently in
clinical trials for the treatment of Crohn’s disease in
which autologous (host-donor, the same individual) and
allogeneic (host-donor, the same species) MSC trans-
plants have been performed [21–23]. MSCs have also
been shown to be neuroprotective in clinical trials and
in a variety of disease models, including multiple sclerosis,
brain and spinal cord injury, stroke, peripheral nerve in-
jury, amyotrophic lateral sclerosis and neurodegenerative
diseases [24–35]. These studies provide the foundation for
investigating the potential efficacy of MSC therapy for the
treatment of enteric neuropathy associated with intestinal
inflammation.
Damage to the enteric nervous system (ENS) correlates
with persistent intestinal inflammation and gut dysfunc-
tion and may provide an avenue for intervention in the
treatment of IBD [36–39]. The ENS functions via a net-
work of neurons and glial cells throughout the length of
the gastrointestinal tract. Neuronal bodies and glial cells
reside within the ganglia comprising two major plexuses:
submucosal and myenteric. Neurons of the submucosal
plexus primarily regulate intestinal secretion and vasodila-
tion, whereas neurons of the myenteric plexus coordinate
muscular contractions [40]. Within the ganglia, individual
neuronal subpopulations have specific functions and are
classified by morphology, electrophysiological properties
and their immunoreactivity to neurochemical markers
associated with the production of different neurotrans-
mitters. In the myenteric plexus, the two major subpop-
ulations of muscle motor neurons and interneurons are
cholinergic and nitrergic. These neurons are identified
by the expression of choline acetyltransferase (ChAT)
and neuronal nitric oxide synthase (nNOS), indicating the
synthesis of acetylcholine and nitric oxide, respectively.
Intestinal inflammation is associated with neuronal
death and axonal damage [41–44]. Additionally, varia-
tions to the neurochemical coding of enteric neurons
have been reported in experimental colitis models and
human IBD biopsies; these changes are not restricted to
sites of active inflammation [42, 45–48]. Specifically,
changes to cholinergic and nitrergic neuronal subpopu-
lations have been reported to be implicated in intestinal
dysmotility [49]. Leukocyte infiltration to the enteric
plexuses is predictive of postoperative disease reoccur-
rence in patients with Crohn’s disease [50–52]. These
observations suggest that neurological changes perpetu-
ate inflammatory relapse and thus the ENS is a viable
target for therapy.
Guinea pigs are the most common species used to
study the functional and morphological properties of the
ENS. The current knowledge of the neurochemical cod-
ing, morphological types and functional classification of
enteric neurons was elucidated in guinea pigs [40, 53].
Since the ENS is embedded within the gastrointestinal
wall, clean dissection and isolation of enteric ganglia are
the main hurdles to study the ENS; these can be more
readily achieved in tissues from guinea pigs compared
with other animals. Electrophysiological, biophysical and
molecular studies of different functional types of enteric
neurons and their ion channels have been performed
predominantly in guinea pigs [53–55].
Experimental models in guinea pigs have significantly
contributed to the understanding of the pathophysiology
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for many human diseases, including cardiovascular, pul-
monary, infectious, auditory and gestational disorders
[56–61]. The 2,4,6-trinitrobenzene-sulfonic acid (TNBS)-
induced model of colitis in guinea pigs has provided
valuable data on functional, morphological and immuno-
histochemical changes of the ENS associated with in-
testinal inflammation [42, 43, 62–65]. The efficacy of
xenogeneic (host-donor, different species) human MSC
treatments has been tested in guinea pig models of
osteoarthritis and radiation damage to the nasal mucosa
[66, 67]. Our recent study in the guinea pig model of
TNBS-induced colitis demonstrated the therapeutic poten-
tial of human MSCs for the treatment of inflammation-
induced enteric neuropathy [68]. These studies may have
benefited from the use of allogeneic MSCs to better repli-
cate transplantation in a clinical setting. Given the value of
guinea pig models in biomedical research, an investigation
establishing the functional efficacy of allogeneic guinea pig
MSCs is warranted. In this study, we present data on the
isolation, in vitro characterisation and in vivo application of
allogeneic MSCs for the treatment of enteric neuropathy
associated with experimental colitis in guinea pigs.
Methods
Animals
Male and female Hartley guinea pigs weighing 140–280 g
were received from the South Australian Health and
Medical Research Institute. All guinea pigs were housed
in a temperature-controlled environment with 12-h
day/night cycles and had ad libitum access to food and
water. All procedures were performed under approval
of the Victoria University Animal Experimentation
Ethics Committee and conducted in accordance with
the Australian National Health and Medical Research
Council Code of Practice for the Care and Use of Animals
for Scientific Purposes.
Isolation of MSCs from guinea pig adipose tissue
Visceral adipose tissue was obtained from guinea pigs.
Tissues were collected in minimum essential medium
with alpha modifications (α-MEM) (Gibco, part of Life
Technologies, Melbourne, Australia) supplemented with
100 U/ml penicillin/streptomycin (Gibco). Samples were
cut into 10-mm strips and incubated at 37 °C for
30 min in 5 ml of α-MEM with 100 U/ml penicillin/
streptomycin and 25 μg/ml liberase™ (Roche, Basel,
Switzerland). The adipose tissue was placed in C-tubes
(Miltenyi Biotec, Bergisch Gladbach, Germany) and
homogenised with a GentleMACS automated dissocia-
tor (Miltenyi Biotec) prior to and after an additional in-
cubation step for 30 min at 37 °C. Enzymatic digestion
was then inhibited by placing tubes on ice and diluting
samples with α-MEM supplemented with penicillin/
streptomycin. The connective tissue was removed via
filtration at 40 μm. Samples were centrifuged at 500 g for
5 min, supernatant was removed and the pellet of cells
was resuspended in 1 ml of expansion medium (α-MEM
supplemented with 100 U/ml penicillin/streptomycin, 1 %
glutaMAX (Gibco) and 16.5 % foetal bovine serum (mes-
enchymal stem cell-qualified; Gibco). Cells were seeded
into culture flasks containing expansion medium which
was replaced every 24 h for 3 days to rid cultures of non-
adherent contaminating cells.
Isolation of guinea pig bone marrow-derived MSCs
Femurs obtained from guinea pigs were transversely cut
along the epiphysis, and the medullary cavity was flushed
with expansion medium by using a 26-G needle to obtain
a bone marrow suspension. To remove debris, the bone
marrow suspension was filtered through a 40-μm Falcon
cell strainer (In Vitro Technologies, Melbourne, Australia)
before being seeded into culture flasks containing expan-
sion medium. The medium was replaced every 24 h for
3 days.
Cell culture and passaging
MSCs derived from guinea pig bone marrow (gpBM-
MSCs) and adipose tissue (gpAT-MSCs) used in this
study were cultured to the fourth passage for all subse-
quent experiments. Cells were plated at an initial density
of 60 cells/cm2 and incubated in expansion medium
which was replenished every 48–72 h for 10–14 days
until the cells were 70–85 % confluent (maximum).
MSCs were trypsinised and either reseeded for expan-
sion or collected for in vitro experiments and in vivo
treatment of guinea pigs.
Surface marker expression
MSCs were immunolabelled as previously described
[69] with CD29-Alexa Fluor 488 (clone TS2/16), CD34-
phycoerythrin (clone 581), CD45-PerCPCy5.5 (clone
H130), CD44-Brilliant Violet 421 (clone IM7), CD73-
Brilliant Violet 421 (clone AD2) and CD90-Alexa Fluor
647 (clone 5E10) (1:100) (BioLegend, San Diego, CA,
USA). Data were acquired on a BD FACSCanto II flow
cytometer with FACSDiva version 6.1 software (BD Biosci-
ences, Sydney, Australia). Unlabelled cells were incubated
with 7-aminoactinomycin D (7-AAD) (1:20) (Life Tech-
nologies, Melbourne, Australia) for 1 minute before acqui-
sition to determine the viability of the cell suspensions.
Differentiation assay
The differentiation potential of MSCs was assessed by
using the StemPro Adipogenesis, Osteogenesis and
Chondrogenesis Differentiation Kits in accordance with
the instructions of the manufacturer (Life Technolo-
gies). To detect adipogenesis, MSCs were fixed in 10 %
neutral buffered formalin after 2 weeks in culture and
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lipid vacuoles were stained with Oil red O (Sigma-Aldrich,
Sydney, Australia) in 60 % (vol/vol) isopropanol. Cells
were then counterstained with haematoxylin. To detect
osteogenesis, MSCs were fixed in 10 % neutral buffered
formalin after 3 weeks in culture and calcium deposits
were stained with 2 % (wt/vol) Alizarin red S (Sigma-
Aldrich) in distilled water. To determine chondrogenic
differentiation, micromass pellets were fixed in 10 %
neutral buffered formalin after 2 weeks in culture and
stained with Alcian blue 8GX (Sigma-Aldrich). Pellets
were embedded in optimal cutting temperature (OCT)
compound (Tissue-Tek; Sakura, Tokyo, Japan) and sec-
tioned at 6 μm for viewing under light microscopy.
Colony-forming unit-fibroblast assay
MSCs were seeded in 90-mm size petri dishes at low
density (100 cells per dish). Expansion medium was
changed every 3–4 days. After 2 weeks in culture, MSCs
were fixed and stained with 0.5 % (wt/vol) crystal violet
(Sigma-Aldrich) in methanol for 30 min before colonies
containing more than 50 cells (colony-forming unit-
fibroblast, or CFU-f ) were counted under a dissection
microscope.
Growth kinetics
MSCs were cultured in triplicates and seeded at 60 cells/
cm2 in 25-cm2 cell culture flasks containing 5 ml of ex-
pansion medium which was replaced every 48–72 h. Cells
were trypsinised and counted with a haemocytometer at
days 3, 7 and 14. The population doubling level (PDL) was
calculated by using the formula PDL = (log2 [final number
of cells]) − (log2 [initial cells seeded]) [70].
Characterisation of MSC cell morphology
MSCs were seeded at 100 cells/cm2 in six-well plates and
analysed after 48 h. MSCs were morphologically charac-
terised into one of two categories defined by the presence
of elongated cell bodies with long thin processes (spindle)
or flat bodies with irregular processes (flat).
Induction of colitis
To induce colitis, TNBS (Sigma-Aldrich) was dissolved
in 30 % ethanol to a concentration of 30 mg/kg and ad-
ministered intrarectally 7 cm proximal to the anus (total
volume of 300 μl) by a lubricated silicone catheter [43].
Guinea pigs were anesthetised with isoflurane (1–4 % in
O2) during the procedure and held at an inverted angle
to prevent leakage. Sham-treated guinea pigs underwent
the same procedure without administration of TNBS.
Administration of MSCs
Guinea pigs were treated with MSCs 3 h after TNBS ad-
ministration at the peak of tissue damage [71]. MSCs
were administered by enema at a dose of 1 × 106 cells in
300 μl of sterile phosphate-buffered saline (PBS). Guinea
pigs were weighed and monitored daily following treat-
ment. At 24 or 72 h after TNBS administration, animals
were culled via stunning and exsanguination [63]. Seg-
ments of the distal colon were collected for histological
and immunohistochemical studies.
Tissue preparation
Colon tissues were cut along the mesenteric border,
stretched and pinned flat with the mucosal side up for
wholemount preparations. Tissue samples were fixed
overnight at 4 °C in Zamboni’s fixative (2 % formalde-
hyde and 0.2 % picric acid) and subsequently washed in
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) (3 × 10 min)
and PBS (3 × 10 min) to remove fixative. Samples for hist-
ology were fixed in 10 % buffered formalin solution and
stored in 70 % ethanol until embedding.
Immunohistochemistry
Immunohistochemistry was performed on wholemount
preparations of the longitudinal muscle and myenteric
plexus. The preparations were dissected by removing the
mucosa, submucosa and circular muscle layers to expose
the myenteric plexus. After 1-h incubation in 10 %
normal donkey serum (Merck Millipore, Melbourne,
Australia) at room temperature, wholemount prepara-
tions were incubated overnight at 4 °C with primary
antibodies: mouse anti-Hu (clone 15A7.1) (1:500)
(Merck Millipore), goat anti-nNOS (1:500) (Novus Bio-
logicals, Littleton, CO, USA), goat anti-ChAT (1:500)
(Merck Millipore), mouse anti-CD45 (clone IH-1) (1:200)
(Abcam, Melbourne, Australia) and rabbit anti-protein
gene product 9.5 (PGP9.5) (1:500) (Abcam). Tissues
were washed (3 × 10 min PBS) and incubated for 2 h at
room temperature with secondary antibodies: donkey
anti-mouse Alexa Fluor 594 (1:200), donkey anti-goat
FITC 488 (1:200), donkey anti-mouse FITC 488 (1:200)
and donkey anti-rabbit Alexa Fluor 594 (1:200) (all from
Jackson ImmunoResearch Laboratories, West Grove, PA,
USA). After washing, tissues were mounted on glass slides
with fluorescent mounting medium (Dako North Amer-
ica, Inc., Carpinteria, CA, USA). For cross-sections, tissues
were frozen in OCT compound and sectioned at a thick-
ness of 30 μm. Cross-sections were labelled with mouse
anti-CD45 (1:200) followed by donkey anti-mouse FITC
488 (1:200) as described above.
Histology
Tissues were embedded in paraffin and cut into 5-μm
sections which were then deparaffinised, cleared, and
rehydrated in graded ethanol. Cross-sections of the
colon were stained with haematoxylin and eosin and
mounted on glass slides with distrene plasticizer xylene
(DPX) mountant. Gross morphological damage in cross-
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sections of the distal colon was assessed by histological
grading of four parameters: mucosal flattening (0 = normal,
3 = severe flattening), occurrence of haemorrhagic sites
(0 = none, 3 = frequent sites), loss of goblet cells (0 =
normal, 3 = severe loss of cells) and variation of the cir-
cular muscle (0 = normal, 3 = considerable thickening of
muscular layer) [62, 68].
Flow cytometric analysis of transforming growth factor-β1
Conditioned media from MSC cultures as described
above were collected at 48 h and analysed on the same
day. Samples and cytokine standards with known con-
centrations were prepared in accordance with the in-
structions of the manufacturer by using the Human
TGF-β1 Single Plex Flex Set (BD Biosciences). Data were
acquired by using a BD FACSCanto II flow cytometer
with FACSDiva version 6.1 software. FCS files were
exported from FACSDiva and analysed with FCAP array
version 3 software (BD Biosciences) to produce standard
curves and measurements of TGF-β1 concentrations
within the sample (in picograms per millilitre). At least
450 events were acquired per sample.
Neuroprotective function of MSC-released TGF-β1 in vitro
Myenteric plexuses were isolated in accordance with a
protocol described by Grundmann et al. [72]. Tissues were
trypsinised for 10 min before cells were seeded into 96-
well plates pre-coated with Matrigel (BD Biosciences) di-
luted 1:10 in medium. Myenteric plexuses were cultured
for 7 days with the medium changed every second day.
Cultures were subjected to lipopolysaccharide (LPS)
(100 ng/ml; Sigma-Aldrich) in conjunction with gpBM-
MSCs or gpAT-MSCs (5 × 104 cells per well), the TGF-β
receptor 1 (TGF-βR1) inhibitor SB431542 (10 μM; Sigma-
Aldrich) or DMSO as a vehicle control. After 3 h, cultures
were washed with PBS and fixed in 10 % neutral buffered
formalin for 1 h. Cells were permeabilised with Triton
X100 (Sigma-Aldrich) and incubated overnight at 4 °C
with the pan-neuronal primary antibody chicken anti-
microtubule-associated protein-2 (anti-MAP-2) (1:5000)
followed by a 2-h incubation with the secondary antibody
donkey anti-chicken Alexa Fluor 594 (1:200).
Imaging
Confocal microscopy was performed by using an
Eclipse Ti confocal laser scanning system (Nikon,
Tokyo, Japan). Fluorophores were visualised by using a
488-nm excitation filter for Alexa 488 or FITC and a
559-nm excitation filter for Alexa 594. Z-series images
were acquired at a nominal thickness of 0.5 μm (512 ×
512 pixels). In wholemount preparations, the total
numbers of myenteric neurons immunoreactive (IR) for
Hu, nNOS, and ChAT as well as CD45-IR cells were
counted within eight randomly captured images (total
area size of 2 mm2) per preparation at a × 60 magnifica-
tion. To evaluate CD45-IR in cross-sections, eight ran-
domly captured images were analysed by using ImageJ
software (National Institutes of Health, Bethesda, MD,
USA). Images were converted from red, green, and blue
(RGB) to grayscale 8 bit then to binary; these images
were then analysed to obtain the total number of CD45
immunoreactive cells within the mucosa, submucosa
and muscle layers in a 650-μm2 area (512 × 512 pixels).
Chondrogenic pellets and haematoxylin and eosin-stained
colon sections were visualised by using an Olympus BX53
microscope (Olympus, Melbourne, Australia), and images
were captured with CellSens™ software (Olympus). Cellu-
lar imaging in vitro was performed on an Olympus IX81
inverted microscope using the same software. In primary
neuronal cultures, images were acquired in a 9-mm2 area
and were analysed by using ImageJ software. Images
were converted from RGB to grayscale 8 bit then to
binary. From these images, the percentage area of
MAP-2 immunoreactivity was measured and presented
relative to untreated primary neuronal cultures to de-
termine neuronal loss.
Statistical analysis
Data analysis was performed by using GraphPad Prism
version 6 (Graphpad Software Inc., La Jolla, CA, USA).
Data were analysed by using Student’s t test (two-tailed)
and one- or two-way analysis of variance when appropri-
ate for multiple group comparisons followed by Tukey’s
and Sidak’s post hoc test. For all analysis, a P value of
less than 0.05 was considered significant. All data were
presented as mean ± standard error of the mean.
Results
In vitro validation of gpBM-MSCs and gpAT-MSCs and
characterisation of their morphology and growth kinetics
To examine the immunophenotype of guinea pig MSCs,
cells were analysed by flow cytometry for the presence
of positive MSC markers CD29, CD44, CD73 and CD90
and negative MSC markers CD34 (hematopoietic progeni-
tors) and CD45 (leukocyte common antigen). Positive ex-
pression of CD29 was observed in both gpBM-MSCs
(95.1 %) and gpAT-MSCs (97.6 %). There was differential
expression of the CD73 antigen such that 85.0 % of
gpBM-MSCs expressed the antigen compared with negli-
gible expression in gpAT-MSCs (0.2 %) (Fig. 1a). Negli-
gible expression of the remaining surface markers was
observed in both cell lines (gpBM-MSC: CD44, 1.9 %;
CD90, 1.5 %; CD34, 4.4 %; CD45, 5.5 %. gpAT-MSC:
CD44, 0.2 %; CD90, 0.2 %; CD34, 0.2 %; CD45, 0.7 %; data
not shown).
Both bone marrow- and adipose tissue-derived MSCs
grew in monolayer culture, adhered to plastic, prolifer-
ated and were typical of MSC appearance (Fig. 1b, b′).
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The clonogenicity of MSCs was compared via a CFU-f
assay. The yield of colony-forming units (>50 cells per
colony [73]) of gpAT-MSCs (17.0 ± 1.3 %) was higher
than that of gpBM-MSCs (1.3 ± 0.5 %, P <0.0001) after
2 weeks in culture (Fig. 1c, c′, d, n = 4 independent cul-
tures per group). To assess the multipotent potential of
MSCs, cells were cultured in specialised media to induce
adipogenic, osteogenic and chondrogenic differentiation.
Lipid vacuoles were present in MSCs cultured in adipo-
genesis differentiation medium when stained with Oil
red O indicative of successful differentiation into adipo-
cytes (Fig. 2a–b′). MSCs cultured in osteogenesis differ-
entiation medium were stained with Alizarin red S,
confirming successful differentiation into osteocytes
(Fig. 2c–d′). MSCs seeded as micromass cultures only
formed pellets in chondrogenesis differentiation medium.
Chondrogenic differentiation was confirmed in the pellets
by Alcian blue staining of cross-sections (Fig. 2e, f ).
MSCs were categorised and quantified according to the
shape of their cell bodies (Fig. 3a–b′). Both gpBM-MSCs
and gpAT-MSCs exhibited two morphological types: long
thin ‘spindle’ (Fig. 3a, b) and ‘flat’ with irregular processes
(Fig. 3a′, b′). Populations of cells with a ‘spindle’ morph-
ology were higher in gpAT-MSCs (63.3 ± 4.9 %) than
gpBM-MSCs (30.0 ± 5.2 %, P <0.001, n = 6 independent
cultures per group; Fig. 3c). Inversely, gpBM-MSC popula-
tions had a higher proportion of cells with a ‘flat’ morph-
ology (70.0 ± 5.2 %) in comparison with gpAT-MSCs
(36.7 ± 4.9 %, P <0.001). The proliferation of MSCs was
quantified over 14 days in culture and presented as the
Fig. 1 Immunophenotype and clonogenicity of guinea pig MSCs from bone marrow and adipose tissue. a GpBM-MSC and gpAT-MSCs were
analysed for cell surface antigen expression of known positive MSC markers CD29 and CD73. Red closed histograms represent MSCs labelled with
antibodies against the surface antigen indicated on the right-hand side of each row. Blue open histograms show isotype controls. GpBM-MSCs
(b) and gpAT-MSCs (b′) adhered to plastic with a perceptible appearance typical of MSCs in culture. Scale bar = 200 μm. The clonogenicity of gpBM-
MSCs (c) and gpAT-MSCs (c′) was determined by a colony-forming unit-fibroblast (CFU-f) assay (n = 4 independent cultures per group). d CFU-f counts
were quantified as a percentage of the total viable cells seeded. ****P <0.0001. gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell,
gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell
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population doubling level (PDL) (Fig. 3d). The PDL of
gpAT-MSCs was higher than that of gpBM-MSCs at 3 days
(2.6 ± 0.1 versus 0.5 ± 0.5, P <0.01), 7 days (6.7 ± 0.1 versus
2.3 ± 0.2, P <0.0001) and 14 days (9.2 ± 0.2 versus 5.6 ±
0.5, P <0.0001) in culture (n = 3 independent cultures per
group per time point).
GpBM-MSCs are more efficacious than gpAT-MSCs in
ameliorating histological damage and weight loss
associated with TNBS-induced colitis
Gross morphological damage was not observed in haema-
toxylin and eosin-stained cross-sections from sham-treated
guinea pigs (histological score = 0; Fig. 4a, a′). Mucosal flat-
tening, haemorrhagic sites, loss of goblet cells and altered
presentation of the circular muscle layer denoting histo-
logical score of 2–3 were observed at 24 and 72 h
following induction of colitis (Fig. 4b, b′). Minimal evi-
dence of mucosal damage or disruption to the colonic
architecture was observed in sections of the colon from
gpBM-MSC-treated animals at both 24 and 72 h after
TNBS administration (histological score = 0–1; Fig. 4c, c′).
Structural changes in crypt architecture, mild mucosal
damage and oedema in the submucosal layer were still
present in colon sections from gpAT-MSC-treated ani-
mals (histological score = 1–2; Fig. 4d, d′).
The body weight of guinea pigs is indicative of over-
all disease progression. Guinea pig body weight was
recorded at 24, 48 and 72 h after treatment (Fig. 4e
and Table 1, n = 4 animals per group per time point). No
statistical differences were observed in weight change at
24 h between all groups. The body weight of TNBS-
administered animals was lower compared with sham
(48 h, P <0.01 and 72 h, P <0.0001) and animals treated
with gpBM-MSCs (48 h, P <0.01 and 72 h, P <0.001) but
not gpAT-MSCs (48 h, P = 0.3 and 72 h, P = 0.7). By 72 h,
gpBM-MSCs were more effective than gpAT-MSCs in
promoting weight gain (P <0.05). At the same time
point, only sham and gpBM-MSC groups had gained
weight (both P <0.0001) which was not observed in
TNBS (P = 1.0) or gpAT-MSC (P = 0.6) groups.
Fig. 2 Differentiation potential of guinea pig MSCs. GpBM-MSCs
and gpAT-MSCs cultured without (a, b) and with (a′, b′) adipogenesis
differentiation medium for 14 days and stained with Oil red O. Scale
bar = 50 μm. GpBM-MSCs and gpAT-MSCs cultured without (c, d) and
with (c′, d′) osteogenesis differentiation medium for 21 days and
stained with Alizarin red S. Scale bar = 200 μm. Alcian blue stained
cross-sections of chondrogenic pellets formed by gpBM-MSCs (e) and
gpAT-MSCs (f) after 14 days in chondrogenic differentiation medium.
Scale bar = 50 μm. gpAT-MSC guinea pig adipose tissue-derived
mesenchymal stem cell, gpBM-MSC guinea pig bone marrow-derived
mesenchymal stem cell, MSC mesenchymal stem cell
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GpBM-MSCs are more efficient in attenuating leukocyte
infiltration to the mucosa and myenteric ganglia
compared with gpAT-MSCs
Leukocyte infiltration to the mucosa, submucosa and
muscle layers was quantified in cross-sections of the
guinea pig colon by using an antibody to the pan-
leukocyte marker CD45 (Fig. 5a–d′, n = 4 animals per
group per time point). Administration of TNBS re-
sulted in an increase in leukocytes at 24 and 72 h within
the mucosa (24 and 72 h, P <0.0001) and submucosa
(24 h, P <0.001 and 72 h, P <0.0001) (Table 2 and Fig. 5e).
Greater leukocyte numbers in TNBS groups were attenu-
ated by treatments with both gpBM-MSCs and gpAT-
MSCs at 24 and 72 h in the mucosa (gpBM-MSC: 24 and
72 h, P <0.01; gpAT-MSCs: 24 h, P <0.05 and 72 h,
P <0.01) and submucosa (gpBM-MSC: 24 h, P <0.05
and 72 h, P <0.0001; gpAT-MSCs: 24 h, P <0.05 and
72 h, P <0.001). However, at 24 h, leukocyte numbers
were higher in the mucosa of gpAT-MSC-treated ani-
mals compared with shams (P <0.05). No differences
in leukocyte infiltration were observed in cross-
sections of the muscle layer. Leukocyte infiltration to
the level of the myenteric plexus was quantified in
wholemount preparations of the guinea pig colon
(Fig. 6a–d′, n = 4 animals per group per time point).
At 24 h, leukocyte numbers were elevated in animals ad-
ministered with TNBS only (107.8 ± 7.2 cells per area)
compared with shams (19 ± 1.2 cells per area, P <0.0001;
Fig. 6e). The infiltration of leukocytes was attenuated by
treatment with both gpBM-MSCs (22 ± 2.9 cells per
area, P <0.0001) and gpAT-MSCs (62 ± 4.6 cells per
area, P <0.001). However, in the latter, leukocytes were
Fig. 3 In vitro morphology and growth kinetics of guinea pig MSCs. a–b′ Distinct morphological subpopulations were exhibited by gpBM-MSCs
(a, a′) and gpAT-MSCs (b, b′) in culture. MSC morphology was defined according to the presence of long thin spindles (‘spindle’: a, b) or flat cells
with atypical processes (‘flat’: a′, b′) (scale bar = 50 μm). c Quantitative analysis of MSC morphological types. Data are expressed as a percentage
of the total cell number in each population (n = 6 independent cultures per group). d The population doubling level of proliferating MSCs was
recorded at 3, 7 and 14 days after seeding (n = 3 independent cultures per group per time point). **P <0.01, ***P <0.001, ****P <0.0001. gpAT-MSC
guinea pig adipose tissue-derived mesenchymal stem cell, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, MSC mesenchymal
stem cell
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Fig. 4 Effects of guinea pig MSC treatments on histological changes and body weight in colitis. Colonic structure was assessed via
haematoxylin-and-eosin staining of cross-sections from tissues collected at 24 h (a–d) and 72 h (a′-d′) after TNBS administration. Scale bar = 50 μm.
e Body weight was recorded at 24, 48 and 72 h after TNBS administration and is expressed as the change from baseline measurements. *P <0.05,
**P <0.01, ***P <0.001, ****P <0.0001, significantly different between groups; †††P <0.001, ††††P <0.0001, significantly different from baseline weight
within groups, n = 4 animals per group per time point. gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell, gpBM-MSC guinea pig
bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell, TNBS 2,4,6-trinitrobenzene sulfonic acid
Table 1 Effects of allogeneic mesenchymal stem cells derived from guinea pigs on body weight (percentage) in TNBS-induced colitis
Sham TNBS TNBS + gpBM-MSC TNBS + gpAT-MSC
24 h 104.3 ± 0.6 99.9 ± 1.6 102.2 ± 0.8 100.2 ± 1.6
48 h 106.8 ± 1.5 100.4 ± 2.4†† 105.9 ± 0.6** 103.0 ± 0.4
72 h 108.8 ± 1.3 100.3 ± 1.0†††† 107.8 ± 1.9*** 102.3 ± 2.1‡ ††
TNBS 2,4,6-trinitrobenzene sulfonic acid, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, gpAT-MSC guinea pig adipose tissue-derived mesenchymal
stem cell. **P <0.01, ***P <0.001, significantly different from TNBS; ††P <0.01, ††††P <0.0001 significantly different from sham; ‡P <0.05, significantly different
from gpBM-MSC
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Fig. 5 Effects of guinea pig MSC treatments on leukocyte infiltration in the colonic wall. a–d′ CD45-IR leukocytes were visualised within the
mucosa, submucosa and muscle layers of the colon. Cross-sections from guinea pig colon collected at 24 h (a–d) and 72 h (a′–d′) after treatment.
Scale bar = 100 μm. e All of the CD45-IR cells were quantified in the mucosa, submucosa and muscle layers within a 650-μm2 area of the colon.
*P <0.05, ***P <0.001, ****P <0.0001, significantly different from sham; †P <0.05, ††P <0.01, †††P <0.001, ††††P <0.0001, significantly different from
TNBS; n = 4 animals per group per time point. gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell, gpBM-MSC guinea pig bone
marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell, TNBS 2,4,6-trinitrobenzene sulfonic acid
Table 2 Effects of in vivo treatment with allogeneic mesenchymal stem cells derived from guinea pigs on CD45 immunoreactive
leukocytes (pixels × 105) in cross-sections of the colon
Sham TNBS TNBS + gpBM-MSC TNBS + gpAT-MSC
Mucosa
24 h 6.71 ± 1.52 26.09 ± 4.47**** 12.97 ± 1.83†† 16.22 ± 1.80†*
72 h 6.00 ± 1.82 24.13 ± 2.65**** 10.54 ± 1.11†† 12.44 ± 1.78††
Submucosa
24 h 0.59 ± 0.17 4.38 ± 0.92*** 2.02 ± 0.41† 1.56 ± 0.46†
72 h 0.48 ± 0.20 5.69 ± 1.22**** 0.82 ± 0.19†††† 1.31 ± 0.10†††
Muscle
24 h 0.57 ± 0.19 2.07 ± 0.48 1.55 ± 0.38 1.96 ± 0.74
72 h 0.68 ± 0.22 1.91 ± 0.36 0.78 ± 0.39 0.76 ± 0.30
TNBS 2,4,6-trinitrobenzene sulfonic acid, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, gpAT-MSC guinea pig adipose tissue-derived mesenchymal
stem cell. †P <0.05, ††P <0.01, †††P <0.001, ††††P <0.0001, significantly different from TNBS; *P <0.05, ***P <0.001, ****P <0.0001, significantly different from sham; n = 4
animals per group per time point
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still elevated compared with sham (P <0.001) and gpBM-
MSC (P <0.001) treated animals. At 72 h, the number
of leukocytes remained elevated in TNBS-administered
animals (80.5 ± 7.3 cells per area) compared with sham
(18.8 ± 1.4 cells per area, P <0.0001) which was de-
creased by both gpBM-MSC (20.5 ± 3.1 cells per area,
P <0.0001) and gpAT-MSC (31.5 ± 3.2 cells per area, P
<0.0001) treatments to levels comparable to those of the
Fig. 6 Effects of treatments with guinea pig MSCs on leukocyte infiltration to the myenteric plexus. a–d′ CD45-IR leukocytes (green) were visualised on
the level of myenteric neurons labelled with anti-PGP9.5 (red) by confocal microscopy. Wholemounts of the myenteric plexus from guinea pig colon
preparations collected at 24 h (a–d) and 72 h (a′-d′) after treatment. Scale bar = 50 μm. e CD45-IR leukocytes were quantified in a 2-mm2 area of the
myenteric plexus in the colon. **P <0.01, ***P <0.001, ****P <0.0001, n = 4 animals per group per time point. gpAT-MSC guinea pig adipose tissue-
derived mesenchymal stem cell, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell, PGP9.5 protein
gene product 9.5
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sham group. Between 24 and 72 h, there was no change
in the levels of leukocytes in sham (P >0.99) and
gpBM-MSC-treated (P >0.99) groups. Conversely, a
decrease in the number of leukocytes was observed in
TNBS (P <0.05) and gpAT-MSC-treated (P <0.01)
groups.
GpBM-MSCs and gpAT-MSCs have comparable efficacy
for attenuating inflammation-induced enteric
neuropathy
To assess the effect of MSC treatments on the total
number of myenteric neurons, anti-HuC/D antibody was
used as a pan-neuronal marker in wholemount prepara-
tions of the guinea pig colon and quantified per 2-mm2
area (Fig. 7a–d′, n = 4 animals per group per time point).
The number of neurons in the myenteric plexus was re-
duced after TNBS administration compared with sham
treatment at both 24 h (P <0.0001) and 72 h (P <0.001;
Table 3 and Fig. 7e). The loss of myenteric neurons was
alleviated by treatment with both gpBM-MSCs (24
and 72 h: P <0.05) and gpAT-MSCs (24 h: P <0.01
and 72 h: P <0.05).
The two major subpopulations of neurons in the my-
enteric plexus, inhibitory and excitatory muscle motor
and interneurons, were investigated [74]. Inhibitory neu-
rons were labelled with anti-nNOS antibody (Fig. 8a–d′),
and the total number of nNOS-IR neurons was quantified
per 2-mm2 area (Fig. 8e and Table 3, n = 4 animals per
group per time point). The number of nNOS-IR neurons
was increased in the myenteric plexus from TNBS groups
compared with sham at 24 h (P <0.01) and 72 h (P <0.05).
The proportion of nNOS-IR neurons to the total number
of Hu-IR neurons was increased in TNBS groups at both
time points compared with sham (24 and 72 h, P <0.001)
(Fig. 8f, n = 4 animals per group per time point). Both
MSC treatments ameliorated the increase in the total
number (gpBM-MSC: 24 and 72 h, P <0.05 and gpAT-
MSC: 24 and 72 h, P <0.01) and proportion of nNOS-IR
neurons at all time points (gpBM-MSC: 24 and 72 h,
P <0.01; gpAT-MSCs: 24 h, P <0.001 and 72 h, P <0.01)
(Fig. 8e, f and Table 3).
Excitatory muscle motor and interneurons were labelled
with anti-ChAT antibodies (Fig. 9a–d′). Quantification of
ChAT-IR neurons revealed a decrease in the total number
of neurons at both 24 and 72 h after TNBS administration
compared with sham (P <0.0001 for both) (Fig. 9e and
Table 3, n = 4 animals per group per time point). The
number of ChAT-IR neurons was higher in groups treated
with gpBM-MSCs and gpAT-MSCs compared with TNBS
alone at both time points (P <0.01 for all) but was less
than in shams (P <0.05 for all). The proportion of ChAT-
IR neurons to the total number of Hu-IR neurons was
quantified; however, no differences were observed between
treatment groups (P = 0.21) (Fig. 9f).
TGF-β1 secreted by guinea pig MSCs attenuates neuronal
loss in vitro
TGF-β1 is a potent anti-inflammatory and neuroprotec-
tive cytokine highly conserved between species. MSCs
were cultured for 48 h before the medium was collected
for flow cytometric quantification of TGF-β1. The in vitro
secretion of TGF-β1 by both gpBM-MSCs (88.4 ± 13.7 pg/
ml) and gpAT-MSCs (88.7 ± 11.5 pg/ml) was observed.
The expansion medium alone served as a control and also
contained TGF-β1 (32.4 ± 11.2 pg/ml), albeit to a lesser
extent than MSC-conditioned media (both P <0.05)
(Fig. 10a, a′).
Primary myenteric neurons were isolated to study the
role of TGF-β1 in MSC-mediated neuroprotection in vitro
(Fig. 10b). Inflammatory conditions were simulated by in-
cubation with LPS (100 ng/ml) for 3 h. Neuronal loss
was observed in cultures incubated with LPS alone
(44.4 ± 6.5 %) or in combination with the vehicle
DMSO (47.3 ± 6.2 %) or the TGF-βR1 inhibitor,
SB431542 (47.7 ± 5.2 %) (P <0.0001 for all). Neuronal
loss was partly attenuated when neurons were co-cul-
tured with gpBM-MSCs and (83.3 ± 6.6 %) gpAT-MSCs
(82.5 ± 4.3 %) in comparison with LPS alone and LPS with
DMSO (P <0.001 for all). The survival of myenteric neu-
rons was decreased by the addition of SB431542 to co-
cultures of neurons with gpBM-MSC (52.0 ± 5.6 %, P
<0.05) or gpAT-MSC (57.8 ± 2.2 %, P <0.01).
Discussion
This study is the first that has evaluated the func-
tional capacity of guinea pig bone marrow and adi-
pose tissue-derived MSCs and determined their
therapeutic value in an animal model of colitis. In
vitro characterisation revealed distinct differences in
growth kinetics, clonogenicity and cell morphology
between MSCs derived from bone marrow and adi-
pose tissue. In an in vivo model of TNBS-induced
colitis, gpBM-MSCs were comparatively more effica-
cious than gpAT-MSCs in attenuating weight loss, co-
lonic tissue damage and leukocyte infiltration into the
myenteric plexus. MSCs from both sources were
equally neuroprotective in the amelioration of enteric
neuronal loss and changes to the neurochemical cod-
ing of neuronal subpopulations.
MSCs were validated and characterised according to
the International Society for Cellular Therapy guide-
lines [9]. Evaluation of surface phenotype revealed that
both gpBM-MSCs and gpAT-MSCs were positive for
CD29 expression. Guinea pig MSCs were negative for
the expression of endothelial and haematopoietic lineage
markers, CD34 and CD45. Previous use of antibodies tar-
geting human surface marker epitopes in guinea pigs has
provided evidence for cross-reactivity in CD34 and CD45
[75]; however, the possibility of false-negative results
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cannot be ruled out entirely. Expression of CD44 and
CD90 was negligible in both types of guinea pig MSCs,
and CD73 was observed only in gpBM-MSCs. The lack of
CD73 expression in adipose tissue-derived MSCs has been
previously reported in mouse [76]. Similar to other MSCs,
gpAT-MSCs were adherent to plastic and successfully
Fig. 7 Effects of guinea pig MSCs on the total number of myenteric neurons. a–d′ Neuronal cell bodies in the myenteric plexus were labelled
with the pan-neuronal marker anti-HuC/D antibody at 24 h a–d and 72 h (a′-d′) after treatment. Scale bar = 50 μm. e The total number of neuronal
bodies was quantified within a 2-mm2 area of the myenteric plexus. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001, n = 4 animals per group per time
point. gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, MSC
mesenchymal stem cell, TNBS 2,4,6-Trinitrobenzene sulfonic acid
Stavely et al. Stem Cell Research & Therapy  (2015) 6:263 Page 13 of 21
differentiated into adipocytes, osteocytes and chondro-
cytes when supplemented with relevant differentiation
media. These traits were previously used to define cells
from the guinea pig as MSCs by Frölich et al. [77] in the
only other study characterising these cells. Our data dem-
onstrated that gpAT-MSCs have greater proliferative cap-
acity than gpBM-MSCs and this is in agreement with their
study [77]. These observations are consistent with studies
in mouse and human MSCs derived from bone marrow
and adipose tissue [27, 78, 79].
Clonogenicity is an important characteristic of MSCs
and is considered to be predictive of their proliferative
and functional capacity [80]. Our data indicate that gpAT-
MSCs have an approximately 13-fold higher proportion of
cells able to form colonies compared with gpBM-MSCs.
Decreased colony formation has been observed in human
bone marrow MSCs compared with adipose tissue MSCs
with CFU-f counts continuing to decline through to the
fourth passage [78]. The CFU-f values of passage four
guinea pig MSCs used in our study were comparable to
the ranges observed by Schellenberg et al. [80] in multiple
human bone marrow and adipose tissue cell lines at the
same passage.
High proliferation rate and spindle-shaped morph-
ology are desired qualities of MSCs; optimising isolation
and in vitro conditions to maintain these traits is one of
the key focuses of MSC research [81–83]. In our study,
gpAT-MSCs appeared to have better MSC qualities in
standard culture, including higher proliferation rate,
colony-forming potential and proportions of spindle-
shaped cells. Comparatively, these traits were suboptimal
in gpBM-MSCs. These results may be directly related to
the heterogeneous subpopulations within MSC cultures
[84]. Similar to our observations in guinea pig MSCs, it
has been reported that rat MSCs from adipose tissue are
more spindle-shaped and have a higher proliferative cap-
acity than those from bone marrow [85]. Given these data,
characterisation of MSCs on the basis of morphology
could be predictive of in vitro proliferation and clonogeni-
city. Thus, differences between the in vitro properties of
MSCs from bone marrow and adipose tissue are regularly
observed in various species. However, there is a lack of re-
search providing comparative evaluation of the thera-
peutic efficacy of MSCs derived from different tissues in
in vivo models of disease.
One of the common models of intestinal inflammation
employs TNBS administration into the colon which acti-
vates the immune response mediated by T helper type 1
cells to hapten-modified autologous proteins [86]. Lack of
weight gain is a symptom of TNBS-induced colitis,
reflecting the general condition of the animal during
the inflamed state [65, 87]. In our study, gpBM-MSC-
treated, but not gpAT-MSC-treated, animals gained
weight by 72 h after the induction of colitis. The ab-
sence of the cell surface enzyme CD73 (5′-nucleotid-
ase) in gpAT-MSCs may be a contributing factor as
the conversion of adenosine monophosphate to extra-
cellular adenosine by CD73 plays a key role in suppressing
the inflammatory response and the T helper type 1
pathway [88]. In our study, gpBM-MSCs alleviated gross
morphological changes in histological cross-sections
of the colon. Conversely, oedema was observed after
Table 3 Effects of allogeneic mesenchymal stem cells derived from guinea pigs on myenteric neurons in TNBS-induced colitis
Sham TNBS TNBS + gpBM-MSC TNBS + gpAT-MSC
Total number of myenteric neurons/2 mm2
24 h 262.6 ± 2.9 204.6 ± 6.9†††† 238.8 ± 6.2* 241.3 ± 8.6**
72 h 261.8 ± 3.9 203.4 ± 4.2††† 241.0 ± 12.7* 238.0 ± 13.2*
Total number of nNOS-IR neurons/2 mm2
24 h 51.8 ± 1.5 68.8 ± 3.9†† 58.5 ± 4.3* 55.5 ± 4.4**
72 h 53.0 ± 1.0 67.6 ± 3.8† 56.0 ± 5.5* 55.8 ± 1.8**
Proportion of nNOS-IR neurons/2 mm2, %
24 h 19.8 ± 0.8 33.8 ± 2.4††† 24.6 ± 2.2** 23.0 ± 1.7***
72 h 20.3 ± 0.3 33.3 ± 1.9††† 23.3 ± 2.0** 23.6 ± 1.3**
Total number of ChAT-IR neurons/2 mm2
24 h 159.6 ± 3.9 111.4 ± 4.0†††† 134.3 ± 5.7†** 135.3 ± 5.7†**
72 h 157.4 ± 4.5 110.2 ± 2.2†††† 137.8 ± 1.5†** 135.3 ± 2.5†**
Proportion of ChAT-IR neurons/2 mm2, %
24 h 60.8 ± 1.6 54.6 ± 2.3 56.7 ± 4.1 56.0 ± 1.3
72 h 60.1 ± 1.2 54.3 ± 2.0 57.6 ± 3.0 57.2 ± 2.1
TNBS 2,4,6-trinitrobenzene sulfonic acid, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, gpAT-MSC guinea pig adipose tissue-derived mesenchymal
stem cell, nNOS neuronal nitric oxide synthase, ChAT choline acetyltransferase, IR immunoreactive. †P <0.05, ††P <0.01, †††P <0.001, ††††P <0.0001, significantly
different from sham; *P <0.05, **P <0.01, ***P <0.001, significantly different from TNBS
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gpAT-MSC treatment. Given the absence of weight
gain, this may indicate that gpAT-MSCs had a re-
duced overall anti-inflammatory effect.
Increased infiltration of leukocytes in the mucosa, sub-
mucosa and myenteric plexus was observed after TNBS
administration which was attenuated by guinea pig MSC
Fig. 8 Effects of guinea pig MSCs on nitrergic myenteric neurons. a–d′ Nitrergic (nNOS-IR) neurons were visualised in the myenteric plexus at
24 h (a–d) and 72 h (a′–d′). Scale bar = 50 μm. The total number of nNOS-IR neurons (e) and the proportion of nNOS-IR neurons to the total
number of HuC/D-IR neurons (f) were quantified within a 2-mm2 area of the myenteric plexus in the guinea pig colon. *P <0.05, **P <0.01, ***P <0.001,
n = 4 animals per group per time point. gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell, gpBM-MSC guinea pig bone
marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell, TNBS 2,4,6-Trinitrobenzene sulfonic acid
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treatments. GpBM-MSCs were more effective than
gpAT-MSCs in reducing the leukocyte infiltrate into the
mucosa and myenteric ganglia at 24 h after treatment.
Differences between the immunomodulatory function of
MSCs derived from bone marrow and adipose tissue
have previously been observed in vitro. Human MSCs
Fig. 9 Effects of guinea pig MSCs on cholinergic myenteric neurons. a–d′ Cholinergic (ChAT-IR) neurons in the myenteric plexus at 24 h (a–d)
and 72 h (a′-d′). Scale bar = 50 μm. The total number of ChAT-IR neurons (e) and the proportion of ChAT-IR neurons to the total number of
HuC/D-IR neurons (f) were quantified within a 2-mm2 area of the myenteric plexus in the guinea pig colon. *P <0.05, **P <0.01, ***P <0.001, n = 4
animals per group per time point. gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell, gpBM-MSC guinea pig bone marrow-
derived mesenchymal stem cell, MSC mesenchymal stem cell, TNBS 2,4,6-Trinitrobenzene sulfonic acid
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Fig. 10 (See legend on next page.)
Stavely et al. Stem Cell Research & Therapy  (2015) 6:263 Page 17 of 21
derived from bone marrow have demonstrated enhanced
prevention of T lymphocyte proliferation and activation
[79], whereas human adipose tissue-derived MSCs su-
periorly prevented monocyte-dendritic cell differenti-
ation and promoted their release of anti-inflammatory
interleukin-10 (IL-10) [89]. In contrast, an investigation
into the ability of MSCs to suppress mixed lymphocyte
reactions and mitogenesis found no differences between
human MSCs from these tissue sources [90]. The results
of in vitro studies are difficult to extrapolate to MSC
functions in vivo; studies in animal models may give a
better understanding of the immunomodulatory differ-
ences between MSCs from bone marrow and adipose
tissue. An optimal tissue source of MSCs for the treat-
ment of disease has not been established. Payne et al.
[32] reported that human adipose tissue MSCs are more
therapeutic than bone marrow MSCs in experimental
autoimmune encephalomyelitis and this is presumably
due to their greater migratory potential. Conversely,
allogeneic MSCs derived from mouse bone marrow
were observed to be more effective in the treatment of
lung inflammation [91, 92]. Furthermore, human bone
marrow MSCs were superior in preventing leukocyte
infiltration into multiple organs in experimental systemic
inflammation [93]. These seemingly polarised outcomes
may suggest that the MSC source yielding optimal efficacy
depends on the targeted pathology.
Administration of TNBS resulted in a loss of myenteric
neurons consistent with other studies in animal models of
experimental colitis [41–43]. No changes to the total
number of neurons were observed between the time
points of this study, demonstrating persistent neuronal
loss after early inflammation. Treatment with guinea pig
MSCs from both tissue sources equally alleviated neuronal
loss. The neurochemical expressions of the two major
subpopulations of myenteric neurons nNOS-IR (nitrergic)
inhibitory and ChAT-IR (cholinergic) excitatory muscle
motor and interneurons were investigated. Administration
of TNBS increased the proportion and the total number
of nitrergic neurons and decreased the total number of
cholinergic neurons. Similar alterations to the neurochem-
ical coding of enteric neurons have been previously re-
ported in experimental colitis [49] and in tissues from
patients with Crohn’s disease [45, 94]. Although nNOS is
traditionally constitutively expressed, previous studies have
also reported increased nNOS expression in neurons of the
central nervous system in response to inflammatory stim-
uli [95, 96]. Mechanisms responsible for this have not yet
been discerned. The proportion of cholinergic neurons in
our study did not decrease and this is consistent with pre-
vious observations and may be attributed to the loss of
total myenteric neurons [42]. Changes to the immunophe-
notype of myenteric neurons are associated with impaired
coordination of muscular contractions and colonic dys-
motility [97, 98]. Our study demonstrated that both types
of guinea pig MSCs inhibited the increase in the number
and proportion of nitrergic neurons and ameliorated the
loss of cholinergic neurons. Similar effects were previously
correlated with the attenuation of inflammation-induced
colonic dysmotility by human bone marrow MSCs [68].
Although gpBM-MSCs were more effective at inhibit-
ing leukocyte infiltration to the level of the myenteric
ganglia, both gpBM-MSCs and gpAT-MSCs were equally
efficient at enteric neuroprotection. This suggests that
MSC-mediated neuroprotection may be directly induced
by the release of neurotrophic factors. Specifically, there
is increasing interest in the neuroprotective value of
TGF-β1 which is secreted by MSCs [99, 100]. Our study
confirmed TGF-β1 secretion in guinea pig MSC cul-
tures; furthermore, levels of secretion were similar in
MSCs from adipose tissue and bone marrow. In in vitro
experiments, both MSCs similarly prevented myenteric
neuronal loss. Furthermore, inhibition of TGF-βR1 ap-
peared to negate the neuroprotective ability of guinea
pig MSCs. TGF-β is widely regarded to have neuropro-
tective roles in the central nervous system for neurode-
generative diseases and ischemic insult [101, 102]. The
function of the TGF-β1 isotype in neuroprotection is
highlighted by Brionne et al. [103], demonstrating that
neurons from TGF-β1−/− mice had poor survival both in
vivo and in culture. Furthermore, neurons from TGF-β1−/+
mice were vulnerable to excitotoxic injury. In human colon
samples, analysis of mRNA from the myenteric plexus de-
tected the presence of all TGF-β isoforms and receptors
with high levels of TGF-β1 and TGF-βR1 [104]. TGF-β1 is
known to be secreted by enteric glial cells critical to
(See figure on previous page.)
Fig. 10 TGF-β1 secreted by guinea pig MSCs contribute to enteric neuroprotection in vitro. a, a′ TGF-β1 secretion was assessed in gpBM-MSC
and gpAT-MSC cultures. MSC-conditioned medium was collected after 48 h, and a bead-based cytometric analysis was performed. The mean
fluorescence intensity (MFI) was recorded by flow cytometry, and a standard curve was generated to determine the concentration of MSC-secreted
TGF-β1. Expansion medium without MSCs served as controls. *P <0.05, n = 6 independent cultures per group. b Primary myenteric neurons quantified
within a 9-mm2 area. Myenteric neurons were incubated with lipopolysaccharide (LPS) to mimic inflammatory conditions. Myenteric neurons were
cultured with a combination of gpBM-MSCs or gpAT-MSCs, the TGF-βR1 inhibitor SB431542 (10 μM) or dimethyl sulfoxide as a vehicle control.
****P <0.0001, significantly different from untreated myenteric neurons; †P <0.05, †††P <0.001, significantly different from LPS + gpBM-MSCs + vehicle;
‡‡P <0.01, ‡‡‡P <0.001, significantly different from LPS + gpAT-MSCs + vehicle; n = 5 independent cultures per group. gpAT-MSC guinea pig adipose tissue-
derived mesenchymal stem cell, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, MSC mesenchymal stem cell, TGF-β1 transforming
growth factor-β1
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maintain neuronal survival and function [105, 106].
Recently, TGF-β secretion by MSCs was reported to
be essential to elicit a therapeutic response in patients
with amyotrophic lateral sclerosis [107]. Furthermore,
TGF-β1 knockdown MSCs are ineffective for the
treatment of ischemic brain injury in rats [108]. Thus,
TGF-β may play a significant role in MSC-mediated
neuroprotection of the ENS.
Conclusions
Guinea pig MSCs are easily isolated from bone marrow
and adipose tissue and exhibit characteristics similar to
those observed in other species. Upon application into
the guinea pig model of inflammation-induced neur-
opathy, allogeneic MSCs demonstrated immunomodu-
latory, trophic and neuroprotective properties. These
data provide evidence of feasibility and functional effi-
cacy of allogeneic MSC transplantation into guinea pig
models. Linking the results of our in vitro and in vivo
experiments, the gpAT-MSC profile of high prolifera-
tion rate, colony-forming potential and an increased
number of cells with ‘spindle’ morphology did not provide
a better therapeutic outcome. Conversely, gpBM-MSCs
which were comparatively suboptimal in these in vitro
traits exerted stronger anti-inflammatory efficacy in the
treatment of plexitis in vivo. Both gpBM-MSCs and gpAT-
MSCs had prominent neuroprotective effects alleviating
neuronal loss and changes in neurochemical expression
induced by intestinal inflammation. The neuroprotective
action of MSCs appeared to be independent of their ability
to prevent immune cell infiltrate. TGF-β1 released by both
types of MSCs might have contributed to the attenuation
of enteric neuropathy associated with colitis.
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